首页 > 最新文献

Journal of Clinical Oncology最新文献

英文 中文
A phase II study of re-introduction of gemcitabine plus cisplatin in combination with durvalumab after durvalumab maintenance therapy in patients with unresectable or recurrent biliary tract cancer (PRIDE study). 一项II期研究,在杜伐单抗维持治疗后,再引入吉西他滨+顺铂联合杜伐单抗治疗不可切除或复发的胆道癌患者(PRIDE研究)。
IF 45.3 1区 医学 Q1 ONCOLOGY Pub Date : 2026-01-01 DOI: 10.1200/jco.2026.44.2_suppl.tps609
Kumiko Umemoto, Ryoji Takada, Tomoyuki Satake, Shunsuke Onoe, Satoshi Shimizu, Hiroshi Nakase, Kenro Hirata, Kazuhiko Shioji, Kazuyuki Matsumoto, Ayako Hata, Kenichiro Tanabe, Makoto Ueno, Junji Furuse, Yu Sunakawa
Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS609-TPS609, January 2026.
临床肿瘤学杂志,第44卷,第2期,第TPS609-TPS609页,2026年1月。
{"title":"A phase II study of re-introduction of gemcitabine plus cisplatin in combination with durvalumab after durvalumab maintenance therapy in patients with unresectable or recurrent biliary tract cancer (PRIDE study).","authors":"Kumiko Umemoto, Ryoji Takada, Tomoyuki Satake, Shunsuke Onoe, Satoshi Shimizu, Hiroshi Nakase, Kenro Hirata, Kazuhiko Shioji, Kazuyuki Matsumoto, Ayako Hata, Kenichiro Tanabe, Makoto Ueno, Junji Furuse, Yu Sunakawa","doi":"10.1200/jco.2026.44.2_suppl.tps609","DOIUrl":"https://doi.org/10.1200/jco.2026.44.2_suppl.tps609","url":null,"abstract":"Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS609-TPS609, January 2026. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"18 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145968677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery NRG BN007的血脑屏障异质性:对免疫治疗递送的影响
IF 45.3 1区 医学 Q1 ONCOLOGY Pub Date : 2026-01-01 DOI: 10.1200/jco-25-02821
Andrew B. Lassman, Mei-Yin C. Polley, Fabio M. Iwamoto, Vinai Gondi, Erik P. Sulman, Jedd D. Wolchok, Minesh P. Mehta
Journal of Clinical Oncology, Ahead of Print.
临床肿瘤学杂志,印刷前。
{"title":"Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery","authors":"Andrew B. Lassman, Mei-Yin C. Polley, Fabio M. Iwamoto, Vinai Gondi, Erik P. Sulman, Jedd D. Wolchok, Minesh P. Mehta","doi":"10.1200/jco-25-02821","DOIUrl":"https://doi.org/10.1200/jco-25-02821","url":null,"abstract":"Journal of Clinical Oncology, Ahead of Print. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"40 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145993087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/DPYD) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing 前处理二氢嘧啶脱氢酶(DPD/DPYD)检测争议的终结加剧了对氟嘧啶适当剂量的争议
IF 45.3 1区 医学 Q1 ONCOLOGY Pub Date : 2026-01-01 DOI: 10.1200/jco-25-02629
Daniel L. Hertz, Alan P. Venook
Journal of Clinical Oncology, Ahead of Print.
临床肿瘤学杂志,印刷前。
{"title":"Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/DPYD) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing","authors":"Daniel L. Hertz, Alan P. Venook","doi":"10.1200/jco-25-02629","DOIUrl":"https://doi.org/10.1200/jco-25-02629","url":null,"abstract":"Journal of Clinical Oncology, Ahead of Print. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"1 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145993088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of ctDNA in early switch of first-line mFOLFIRINOX in metastatic pancreatic ductal adenocarcinoma (mPDAC). ctDNA在转移性胰腺导管腺癌(mPDAC)一线mFOLFIRINOX早期转换中的应用
IF 45.3 1区 医学 Q1 ONCOLOGY Pub Date : 2026-01-01 DOI: 10.1200/jco.2026.44.2_suppl.tps799
Isildinha M. Reis, Jashodeep Datta, Yolanda Justal, Peter Joel Hosein
Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS799-TPS799, January 2026.
临床肿瘤学杂志,第44卷,第2期,第TPS799-TPS799页,2026年1月。
{"title":"Utility of ctDNA in early switch of first-line mFOLFIRINOX in metastatic pancreatic ductal adenocarcinoma (mPDAC).","authors":"Isildinha M. Reis, Jashodeep Datta, Yolanda Justal, Peter Joel Hosein","doi":"10.1200/jco.2026.44.2_suppl.tps799","DOIUrl":"https://doi.org/10.1200/jco.2026.44.2_suppl.tps799","url":null,"abstract":"Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS799-TPS799, January 2026. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"266 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145968655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase 1/2 study of ARV-806, a PROTAC KRAS G12D degrader, in KRAS G12D–mutated advanced solid tumors, including pancreatic cancer. PROTAC KRAS G12D降降剂ARV-806在KRAS G12D突变的晚期实体肿瘤(包括胰腺癌)中的1/2期研究。
IF 45.3 1区 医学 Q1 ONCOLOGY Pub Date : 2026-01-01 DOI: 10.1200/jco.2026.44.2_suppl.tps792
Patricia LoRusso, Ignacio Garrido-Laguna, Benjamin Herzberg, Amita Patnaik, Neel Jitendra Gandhi, Kathryn Smith, Lori Cykowski, Xin Zhi, Diane I. Healey, Vaibhav G. Patel, David S. Hong
Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS792-TPS792, January 2026.
临床肿瘤学杂志,第44卷,第2期,TPS792-TPS792页,2026年1月。
{"title":"Phase 1/2 study of ARV-806, a PROTAC KRAS G12D degrader, in KRAS G12D–mutated advanced solid tumors, including pancreatic cancer.","authors":"Patricia LoRusso, Ignacio Garrido-Laguna, Benjamin Herzberg, Amita Patnaik, Neel Jitendra Gandhi, Kathryn Smith, Lori Cykowski, Xin Zhi, Diane I. Healey, Vaibhav G. Patel, David S. Hong","doi":"10.1200/jco.2026.44.2_suppl.tps792","DOIUrl":"https://doi.org/10.1200/jco.2026.44.2_suppl.tps792","url":null,"abstract":"Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS792-TPS792, January 2026. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"4 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145968661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A phase Ib/II, dose escalation and dose expansion study of valemetostat tosylate (DS-3201b) with atezolizumab and bevacizumab in advanced hepatocellular carcinoma (HCC). 缬美托他tosylate (DS-3201b)联合atezolizumab和bevacizumab治疗晚期肝细胞癌(HCC)的Ib/II期剂量递增和剂量扩展研究。
IF 45.3 1区 医学 Q1 ONCOLOGY Pub Date : 2026-01-01 DOI: 10.1200/jco.2026.44.2_suppl.tps613
Charity Morgan, Ahmet Anil Ozluk, S.M. Qasim Hussaini, Garima Gupta, Darryl Alan Outlaw, Alexander Bray, Midhun Malla, Bassel F. El-Rayes
Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS613-TPS613, January 2026.
临床肿瘤学杂志,第44卷,第2_增刊,TPS613-TPS613页,2026年1月。
{"title":"A phase Ib/II, dose escalation and dose expansion study of valemetostat tosylate (DS-3201b) with atezolizumab and bevacizumab in advanced hepatocellular carcinoma (HCC).","authors":"Charity Morgan, Ahmet Anil Ozluk, S.M. Qasim Hussaini, Garima Gupta, Darryl Alan Outlaw, Alexander Bray, Midhun Malla, Bassel F. El-Rayes","doi":"10.1200/jco.2026.44.2_suppl.tps613","DOIUrl":"https://doi.org/10.1200/jco.2026.44.2_suppl.tps613","url":null,"abstract":"Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS613-TPS613, January 2026. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"32 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145968673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First-line (1L) trastuzumab deruxtecan (T-DXd) with volrustomig and fluoropyrimidine in patients with HER2-low gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) part 5. 低her2胃癌(GC)、胃食管交界处腺癌(GEJA)或食管腺癌(EA)患者的一线(1L)曲妥珠单抗德鲁西替康(T-DXd)联合volrustomig和氟嘧啶:DESTINY-Gastric03 (DG-03)第5部分。
IF 45.3 1区 医学 Q1 ONCOLOGY Pub Date : 2026-01-01 DOI: 10.1200/jco.2026.44.2_suppl.tps472
Hanneke W.M. Van Laarhoven, Roy Rabbie, Caron Lloyd, Zhuoer Sun, Jeeyun Lee
Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS472-TPS472, January 2026.
临床肿瘤学杂志,第44卷,第2期,TPS472-TPS472页,2026年1月。
{"title":"First-line (1L) trastuzumab deruxtecan (T-DXd) with volrustomig and fluoropyrimidine in patients with HER2-low gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) part 5.","authors":"Hanneke W.M. Van Laarhoven, Roy Rabbie, Caron Lloyd, Zhuoer Sun, Jeeyun Lee","doi":"10.1200/jco.2026.44.2_suppl.tps472","DOIUrl":"https://doi.org/10.1200/jco.2026.44.2_suppl.tps472","url":null,"abstract":"Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS472-TPS472, January 2026. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"24 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145968682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CLARITY-Gastric 01: A randomized phase 3 study of sonesitatug vedotin (sone ve), a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC). CLARITY-Gastric 01:一项针对CLDN18.2 (CLDN18.2)靶向抗体-药物偶联物sonesitatug vedotin (soneve)的随机3期研究,用于二线或二线(2L+)晚期胃癌或胃食管结癌(GC/GEJC)。
IF 45.3 1区 医学 Q1 ONCOLOGY Pub Date : 2026-01-01 DOI: 10.1200/jco.2026.44.2_suppl.tps462
Yelena Y. Janjigian, Elena Elimova, Jun Zhang, Ming-Huang Chen, Elizabeth Catherine Smyth, Jeeyun Lee, Rui Miao, Silver Liu, Marielle Holmblad, Osama E. Rahma, Rui-Hua Xu
Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS462-TPS462, January 2026.
临床肿瘤学杂志,第44卷,第2期,TPS462-TPS462页,2026年1月。
{"title":"CLARITY-Gastric 01: A randomized phase 3 study of sonesitatug vedotin (sone ve), a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC).","authors":"Yelena Y. Janjigian, Elena Elimova, Jun Zhang, Ming-Huang Chen, Elizabeth Catherine Smyth, Jeeyun Lee, Rui Miao, Silver Liu, Marielle Holmblad, Osama E. Rahma, Rui-Hua Xu","doi":"10.1200/jco.2026.44.2_suppl.tps462","DOIUrl":"https://doi.org/10.1200/jco.2026.44.2_suppl.tps462","url":null,"abstract":"Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS462-TPS462, January 2026. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"38 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145968692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery NRG BN007的血脑屏障异质性:对免疫治疗递送的影响
IF 45.3 1区 医学 Q1 ONCOLOGY Pub Date : 2026-01-01 DOI: 10.1200/jco-25-01988
Xuan Wang, Xudong Li, Xiaobing Jiang
Journal of Clinical Oncology, Ahead of Print.
临床肿瘤学杂志,印刷前。
{"title":"Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery","authors":"Xuan Wang, Xudong Li, Xiaobing Jiang","doi":"10.1200/jco-25-01988","DOIUrl":"https://doi.org/10.1200/jco-25-01988","url":null,"abstract":"Journal of Clinical Oncology, Ahead of Print. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"28 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145993100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RIVER-mPDAC: A phase 2b/3 study of ponsegromab for the treatment of cachexia in patients with metastatic pancreatic ductal adenocarcinoma receiving first-line chemotherapy. RIVER-mPDAC: ponsegromab治疗接受一线化疗的转移性胰腺导管腺癌患者的恶病质的2b/3期研究。
IF 45.3 1区 医学 Q1 ONCOLOGY Pub Date : 2026-01-01 DOI: 10.1200/jco.2026.44.2_suppl.tps791
Imran Yousuf Ali, Timothy R. Asmis, Jeffrey Crawford, Richard Francis Dunne, Marie T. Fallon, Alexandra Palmer, Glenn Pixton, Jan Kiszko, Keith D. Wilner, Andrew Hendifar
Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS791-TPS791, January 2026.
临床肿瘤学杂志,第44卷,第2期,TPS791-TPS791页,2026年1月。
{"title":"RIVER-mPDAC: A phase 2b/3 study of ponsegromab for the treatment of cachexia in patients with metastatic pancreatic ductal adenocarcinoma receiving first-line chemotherapy.","authors":"Imran Yousuf Ali, Timothy R. Asmis, Jeffrey Crawford, Richard Francis Dunne, Marie T. Fallon, Alexandra Palmer, Glenn Pixton, Jan Kiszko, Keith D. Wilner, Andrew Hendifar","doi":"10.1200/jco.2026.44.2_suppl.tps791","DOIUrl":"https://doi.org/10.1200/jco.2026.44.2_suppl.tps791","url":null,"abstract":"Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS791-TPS791, January 2026. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"40 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145968663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1